{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T12:10:34Z","timestamp":1734437434645,"version":"3.30.2"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"DOI":"10.7759\/cureus.75864","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:42:21Z","timestamp":1734435741000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-melanoma Differentiation-Associated Protein 5 (MDA5)-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease (ILD): A Rare and Lethal Entity to Recognize Early"],"prefix":"10.7759","author":[{"given":"Rita","family":"Bernardino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Valente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concei\u00e7\u00e3o","family":"Loureiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas MC","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015, 372:1734-47. 10.1056\/NEJMra1402225","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14227","article-title":"Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort","volume":"174","author":"Galimberti F","year":"2016","unstructured":"Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016, 174:158-64. 10.1111\/bjd.14227","journal-title":"Br J Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.1042","article-title":"Rapidly progressive interstitial lung disease in association with MDA5 antibody dermatomyositis","volume":"158","author":"Kazmierski D","year":"2020","unstructured":"Kazmierski D, Sharma N. Rapidly progressive interstitial lung disease in association with MDA5 antibody dermatomyositis. Chest. 2020, 158:1648. 10.1016\/j.chest.2020.08.1042","journal-title":"Chest"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12948-015-0031-y","article-title":"MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations","volume":"13","author":"Parronchi P","year":"2015","unstructured":"Parronchi P, Radice A, Palterer B, Liotta F, Scaletti C. MDA5-positive dermatomyositis: an uncommon entity in Europe with variable clinical presentations. Clin Mol Allergy. 2015, 13:22. 10.1186\/s12948-015-0031-y","journal-title":"Clin Mol Allergy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.07.2171","article-title":"An unusual presentation of amyopathic dermatomyositis with interstitial lung disease","volume":"164","author":"Dhillon V","year":"2023","unstructured":"Dhillon V, Menakuru S. An unusual presentation of amyopathic dermatomyositis with interstitial lung disease. Chest. 2023, 164:2171. 10.1016\/j.chest.2023.07.2171","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-021-00186-x","article-title":"Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease","volume":"7","author":"Selva-O'Callaghan A","year":"2021","unstructured":"Selva-O'Callaghan A, Romero-Bueno F, Trallero-Aragu\u00e1s E, Gil-Vila A, Ruiz-Rodr\u00edguez JC, S\u00e1nchez-Pernaute O, Pinal-Fern\u00e1ndez I. Pharmacologic treatment of anti-MDA5 rapidly progressive interstitial lung disease. Curr Treatm Opt Rheumatol. 2021, 7:319-33. 10.1007\/s40674-021-00186-x","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkab024","article-title":"Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series","volume":"5","author":"Dick M","year":"2021","unstructured":"Dick M, Martin J, Tugnet N. Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease-an Auckland case series. Rheumatol Adv Pract. 2021, 5:rkab024. 10.1093\/rap\/rkab024","journal-title":"Rheumatol Adv Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","article-title":"Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies","volume":"12","author":"Nombel A","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021, 12:773352. 10.3389\/fimmu.2021.773352","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.833114","article-title":"Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system","volume":"8","author":"Hu H","year":"2021","unstructured":"Hu H, Yang H, Liu Y, Yan B. Pathogenesis of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: a concise review with an emphasis on type I interferon system. Front Med (Lausanne). 2021, 8:833114. 10.3389\/fmed.2021.833114","journal-title":"Front Med (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03100-z","article-title":"Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody","volume":"25","author":"Wang H","year":"2023","unstructured":"Wang H, Chen X, Du Y, et al.. Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody. Arthritis Res Ther. 2023, 25:127. 10.1186\/s13075-023-03100-z","journal-title":"Arthritis Res Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.09.002","article-title":"Immunization strategies to span the spectrum of immunocompromised adults","volume":"95","author":"Whitaker JA","year":"2020","unstructured":"Whitaker JA. Immunization strategies to span the spectrum of immunocompromised adults. Mayo Clin Proc. 2020, 95:1530-48. 10.1016\/j.mayocp.2019.09.002","journal-title":"Mayo Clin Proc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu X","year":"2024","unstructured":"Lu X, Peng Q, Wang G. Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2024, 20:48-62. 10.1038\/s41584-023-01054-9","journal-title":"Nat Rev Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2023-eular.5057","article-title":"RP-ILD in patients with anti-MDA5 positive antibodies: clinical evaluation and prognosis. Retrospective data from a single center cohort","volume":"82","author":"Ienna L","year":"2023","unstructured":"Ienna L, Iaccarino L, Doria A, et al.. RP-ILD in patients with anti-MDA5 positive antibodies: clinical evaluation and prognosis. Retrospective data from a single center cohort. Ann Rheum Dis. 2023, 82:1672-3. 10.1136\/annrheumdis-2023-eular.5057","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/326007-anti-melanoma-differentiation-associated-protein-5-mda5-positive-dermatomyositis-with-rapidly-progressive-interstitial-lung-disease-ild-a-rare-and-lethal-entity-to-recognize-early","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T11:42:22Z","timestamp":1734435742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/326007-anti-melanoma-differentiation-associated-protein-5-mda5-positive-dermatomyositis-with-rapidly-progressive-interstitial-lung-disease-ild-a-rare-and-lethal-entity-to-recognize-early"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.75864","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,17]]}}}